Gyre Therapeutics, Inc. (NASDAQ:GYRE) President Sells $25,400.00 in Stock

Gyre Therapeutics, Inc. (NASDAQ:GYRE) President Songjiang Ma sold 2,000 shares of the company’s stock in a transaction on Thursday, December 26th. The shares were sold at an average price of $12.70, for a total value of $25,400.00. Following the transaction, the president now directly owns 2,928,467 shares in the company, valued at $37,191,530.90. This represents a 0.07 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Songjiang Ma also recently made the following trade(s):

• On Monday, December 23rd, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The stock was sold at an average price of $12.27, for a total value of $24,540.00.
• On Thursday, December 19th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $10.82, for a total transaction of $21,640.00.
• On Tuesday, December 17th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The stock was sold at an average price of $11.05, for a total transaction of $22,100.00.

Gyre Therapeutics Stock Performance

Gyre Therapeutics stock opened at $12.10 on Thursday. The firm’s fifty day moving average price is $12.64 and its 200-day moving average price is $12.67. Gyre Therapeutics, Inc. has a fifty-two week low of $8.26 and a fifty-two week high of $27.45.

Hedge Funds Weigh In On Gyre Therapeutics

Institutional investors have recently modified their holdings of the company. Charles Schwab Investment Management Inc. raised its position in Gyre Therapeutics by 392.2% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 113,648 shares of the company’s stock worth $1,425,000 after purchasing an additional 90,557 shares during the period. Geode Capital Management LLC raised its position in Gyre Therapeutics by 16.9% during the 3rd quarter. Geode Capital Management LLC now owns 303,647 shares of the company’s stock valued at $3,808,000 after purchasing an additional 43,840 shares during the last quarter. Advantage Alpha Capital Partners LP purchased a new stake in Gyre Therapeutics in the third quarter worth $334,000. WINTON GROUP Ltd purchased a new stake in shares of Gyre Therapeutics in the 2nd quarter worth about $220,000. Finally, Bank of New York Mellon Corp bought a new stake in Gyre Therapeutics during the 2nd quarter valued at approximately $218,000. 23.99% of the stock is currently owned by institutional investors.

Gyre Therapeutics Company Profile

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.